OPNT - Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Opiant Pharmaceuticals (OPNT) has announced an additional commitment of up to $3.5M from the Biomedical Advanced Research and Development Authority (BARDA), to accelerate the development of OPNT003, nasal nalmefene, for opioid overdose.The contract modification increases the total potential value of the BARDA contract to $8.1M.Previously, the company received $4.6M from BARDA, as well as $7.4M grant from the National Institute on Drug Abuse. The additional BARDA support will fund both a planned pharmacodynamic study in healthy volunteers and development work associated with the use of Aptar Pharma’s Unit Dose System.

For further details see:

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003